University of Groningen

Anticoagulation in Atrial Fibrillation

Jacobs, Maartje

DOI:
[10.33612/diss.132895541](https://doi.org/10.33612/diss.132895541)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):
Jacobs, M. (2020). *Anticoagulation in Atrial Fibrillation: Consideration for treatment and health economic aspects*. [Thesis fully internal (DIV), University of Groningen]. University of Groningen.
<https://doi.org/10.33612/diss.132895541>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Anticoagulation in Atrial Fibrillation

Consideration for treatment and health economic aspects

Maartje Jacobs

Financial support for printing this thesis was kindly provided by the University of Groningen, University Medical Center Groningen, Research Institute SHARE, Martini Ziekenhuis and Federatie van Nederlandse Trombosediensten

Artwork: Gaby Jacobs-Alink

Lay-out: Lara Leijtens | persoonlijkproefschrift.nl

Print: Ridderprint | www.ridderprint.nl

© Maartje Jacobs, 2020

All rights reserved. No part of this thesis may be reproduced or transmitted in any form or by any means without permission of the author

rijksuniversiteit
 groningen

Anticoagulation in Atrial Fibrillation

Consideration for treatment and health economic aspects

Proefschrift

ter verkrijging van de graad van doctor aan de
Rijksuniversiteit Groningen
op gezag van de
rector magnificus prof. dr. C. Wijmenga
en volgens besluit van het College voor Promoties.

De openbare verdediging zal plaatsvinden op
woensdag 30 september 2020 om 12.45 uur

door

Maartje Sara Jacobs

geboren op 26 mei 1988
te Meppel

Promotor

Prof. dr. M.J. Postma

Copromotores

Dr. M. van Hulst

Dr. R.G. Tieleman

Beoordelingscommissie

Prof. dr. H. Buller

Prof. dr. L. Annemans

Prof. dr. B. Wilffert

TABLE OF CONTENT

Part A- Screening, Stroke Prevention, Atrial Fibrillation Treatment Aspects		8
Chapter 1	General introduction and scope of the thesis	10
Chapter 2	Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands <i>Europace. 2018;20(1):12–18</i>	22
Chapter 3	Atrial fibrillation in Africa - an underreported and unrecognized risk factor for stroke: a systematic review <i>Global Heart. 2019;14(3):269–279</i>	38
Chapter 4	Screening for atrial fibrillation in Sub-Saharan Africa: a health economic evaluation to assess the feasibility in Nigeria <i>Submitted for publication</i>	60
Chapter 5	Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions. <i>Netherlands Heart Journal. 2019;27(7-8):371–377</i>	78
Chapter 6	Secondary adherence to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation in Sweden and the Netherlands <i>Current Medical Research and Opinion. 2018;34(10):1839–1847</i>	92
Chapter 7	Predictors for health care costs and cardiology costs in AF patients initiating dabigatran or acencoumarol <i>Journal of Medical Economics. 2017;20(12):1231–1236</i>	112

Part B- Focus on Specific AF Subpopulations		126
Chapter 8	Optimal treatment of patients with atrial fibrillation undergoing a coronary intervention: triple therapy is too much! <i>Netherlands Heart Journal. 2018;26(6):334–340</i>	128
Chapter 9	The incidence, treatment and mortality of new-onset atrial fibrillation patients at the intensive care unit <i>Open Heart 2020;0:e001226. doi:10.1136/openhrt-2019-001226</i>	142
Chapter 10	Perioperative Bridging of Vitamin K Antagonist Treatment in Patients with Atrial Fibrillation: Only a Very Small Group of Patients Benefits <i>Europace. 2019;21(5):716–723</i>	156
Chapter 11	Cost-effectiveness of elective electrical cardioversion of atrial fibrillation of rivaroxaban compared to vitamin K oral antagonists <i>European Journal of Health Economics. 2018;19(7):957–965</i>	172
Chapter 12	Discussion	188
Appendix I	Nederlandse samenvatting	206
Appendix II	English summary	213
Appendix III	Publications: thesis & non-thesis	219
Appendix IV	SHARE previous dissertations	223
Appendix V	Curriculum vitae	227
Appendix VI	Acknowledgements	229

Part

A

**Screening, Stroke Prevention,
Atrial Fibrillation Treatment
Aspects**